908 Devices (NASDAQ:MASS – Free Report) had its price objective cut by Stifel Nicolaus from $17.00 to $6.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.
Separately, Leerink Partners restated a “market perform” rating and issued a $4.00 price target (down from $12.00) on shares of 908 Devices in a research report on Wednesday.
Read Our Latest Stock Analysis on MASS
908 Devices Price Performance
Institutional Investors Weigh In On 908 Devices
A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in shares of 908 Devices in the 3rd quarter worth about $36,000. GAMMA Investing LLC acquired a new stake in shares of 908 Devices in the second quarter valued at approximately $48,000. Drive Wealth Management LLC bought a new stake in shares of 908 Devices during the third quarter valued at approximately $50,000. Townsquare Capital LLC bought a new stake in shares of 908 Devices during the third quarter valued at approximately $50,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of 908 Devices during the first quarter worth approximately $80,000. 88.06% of the stock is currently owned by institutional investors.
908 Devices Company Profile
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Featured Articles
- Five stocks we like better than 908 Devices
- Investing In Preferred Stock vs. Common Stock
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What Does a Stock Split Mean?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Invest in the FAANG Stocks
- Time to Load Up on Home Builders?
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.